醫學系泌尿學科

Keyphrases

1. Adjusted Hazard Ratio 11%
2. After Surgery 12%
3. Androgen Deprivation Therapy 34%
4. Arsenic 13%
5. Autoimmune Disease 9%
6. Benign Prostatic Hyperplasia 19%
7. Bladder Cancer 18%
8. Bladder Cuff Excision 16%
9. Bladder Neck Contracture 13%
10. Breast Cancer Cells 9%
11. Cancer-specific Survival 14%
12. Castration-resistant Prostate Cancer 13%
13. Clinical Experience 12%
14. Clinical Outcomes 10%
15. Clinically Significant Prostate Cancer 12%
16. Comorbidity 10%
17. Complication Rate 18%
18. Confidence Interval 43%
19. Disease-free Survival 13%
20. Elderly Patients 12%
21. Escherichia Coli 10%
22. Estrogen 10%
23. Extracorporeal Shock Wave Lithotripsy 11%
24. Hand-assisted Retroperitoneoscopic Donor Nephrectomy 10%
25. Hazard Ratio 16%
26. High Risk 14%
27. Insufflation 9%
28. Kidney 19%
29. Laparoscopic Adrenalectomy 9%
30. Laparoscopic Partial Nephrectomy 45%
31. Laparoscopic Radical Prostatectomy 9%
32. Laparoscopic Surgery 18%
33. Laparoscopy 10%
34. Latanoprost 11%
35. Magnetic Resonance Imaging 16%
36. Meta-analysis 9%
37. Metastatic Castration-resistant Prostate Cancer (mCRPC) 10%
38. Monoamine Oxidase A (MAO-A) 14%
39. Multiparametric MRI (mpMRI) 10%
40. Multivariate Analysis 10%
41. National Cohort Study 48%
42. National Health Insurance Research Database (NHIRD) 10%
43. Nephroureterectomy 31%
44. Neuroendocrine Differentiation 9%
45. Neuroendocrine Prostate Cancer 12%
46. Newly Diagnosed 13%
47. No Significant Difference 11%
48. Non-muscle Invasive Bladder Cancer (NMIBC) 12%
49. Odds Ratio 12%
50. Oncological Outcomes 18%
51. Operative Time 20%
52. Overall Survival 13%
53. Overexpression 9%
54. Partial Nephrectomy 10%
55. Patients with Prostate Cancer 14%
56. Percutaneous Nephrolithotomy 14%
57. Perioperative Complications 9%
58. Pharmacokinetics 11%
59. Population-based Study 27%
60. Porcine Model 12%
61. Postpartum Depression 11%
62. Prostate 23%
63. Prostate Cancer 76%
64. Prostate Cancer Cells 21%
65. Prostate Cancer Patients 18%
66. Prostate Cancer Screening 14%
67. Prostate Health Index 13%
68. Prostate-specific Antigen 10%
69. Radical Cystectomy 12%
70. Radical Prostatectomy 16%
71. Recurrence-free Survival 9%
72. Renal Cell Carcinoma 19%
73. Renal Tissue 9%
74. Retroperitoneoscopic 10%
75. Risk Factors 17%
76. Scabies 26%
77. Shock Wave Lithotripsy 10%
78. Single-center Experience 17%
79. Single-center Study 9%
80. Stone-free Rate 17%
81. Surgical Outcomes 10%
82. Systematic Meta-analysis 12%
83. Taipei 39%
84. Taiwan 100%
85. Taiwanese 14%
86. Thulium Laser 15%
87. Traditional Chinese Medicine 9%
88. Transitional Cell Carcinoma 20%
89. Transrectal Biopsy 10%
90. Transurethral Resection of Prostate 21%
91. Tumor 26%
92. Tumor Size 10%
93. Upper Tract Urothelial Carcinoma 42%
94. Ureter 19%
95. Ureteral Stone 10%
96. Urinary Tract Infection 10%
97. Urolithiasis 11%
98. Urothelial Carcinoma 16%
99. Varicocele 11%
100. Younger Schoolchildren 9%

Medicine and Dentistry

1. Adrenal Incidentaloma 6%
2. Adrenal Tumor 9%
3. Adrenalectomy 15%
4. Adverse Event 9%
5. Amine Oxidase (Flavin Containing) Isoenzyme A 7%
6. Androgen Deprivation Therapy 13%
7. Autoimmune Disease 6%
8. Biopsy Technique 22%
9. Bladder 45%
10. Bladder Cancer 15%
11. Bladder Neck 6%
12. Bladder Neck Stenosis 13%
13. Bleeding 18%
14. Body Mass Index 12%
15. Cancer Diagnosis 8%
16. Cancer Specific Survival 9%
17. Cancer Staging 6%
18. Castration Resistant Prostate Cancer 12%
19. Cell Signaling Pathway 12%
20. Clear Cell Renal Cell Carcinoma 21%
21. Cohort Analysis 34%
22. Comorbidity 9%
23. Computer Assisted Tomography 12%
24. Cystectomy 18%
25. Diabetes Mellitus 6%
26. Disease Free Survival 11%
27. Diseases 22%
28. Elderly Patient 9%
29. Emergency Department 7%
30. Extracorporeal Shock Wave Lithotripsy 9%
31. Gleason Score 6%
32. Hazard Ratio 22%
33. Hernioplasty 8%
34. Hormone Therapy 8%
35. Incision 17%
36. Infection 11%
37. Intraocular Pressure 7%
38. Kidney Blood Flow 6%
39. Kidney Function 8%
40. Kidney Stone 25%
41. Laparoscopic Surgery 36%
42. Ligation 15%
43. Lithotripsy 21%
44. Magnetic Resonance Imaging 15%
45. Malignant Neoplasm 16%
46. Messenger RNA 7%
47. Meta-Analysis 6%
48. Metastatic Carcinoma 8%
49. Minimally Invasive Procedure 6%
50. Mitochondrion 9%
51. Mitogen Activated Protein Kinase 3 7%
52. Multivariate Analysis 9%
53. Neoplasm 55%
54. Nephrectomy 16%
55. Nephroureterectomy 51%
56. Non Muscle Invasive Bladder Cancer 8%
57. Odds Ratio 19%
58. Operation Duration 19%
59. Overall Survival 17%
60. Partial Nephrectomy 25%
61. Pelvis 12%
62. Percutaneous Nephrolithotomy 14%
63. Peroperative Complication 12%
64. Pheochromocytoma 8%
65. Pneumoperitoneum 6%
66. Pneumoretroperitoneum 6%
67. Postoperative Complication 7%
68. Prevalence 8%
69. Programmed Cell Death 9%
70. Proportional Hazards Model 11%
71. Prostate Biopsy 14%
72. Prostate Cancer 77%
73. Prostate Hypertrophy 12%
74. Prostate Specific Antigen 20%
75. Prostatectomy 22%
76. Radiation Therapy 9%
77. Recurrence Free Survival 6%
78. Recurrent Disease 16%
79. Retreatment 6%
80. Retrospective Study 14%
81. Scabies 26%
82. Shock Wave 12%
83. Staghorn Stone 6%
84. Surgeon 7%
85. Surgery 17%
86. Survival Rate 8%
87. Systematic Review 6%
88. Testes 10%
89. Thulium 15%
90. Transitional Cell Carcinoma 68%
91. Transrectal Ultrasonography 18%
92. Transurethral Resection 23%
93. Upper Urinary Tract 26%
94. Ureter 14%
95. Ureter Stone 9%
96. Urinary Retention 9%
97. Urinary System 17%
98. Urinary Tract 11%
99. Urinary Tract Infection 8%
100. Urothelial Cancer 8%